Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
The Korean Journal of Internal Medicine ; : 263-273, 2013.
Artículo en Inglés | WPRIM | ID: wpr-35113

RESUMEN

Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be selected for young and elderly subjects. Young patients are commonly eligible for transplantation, which is now considered the standard approach for this setting, and various inductions therapies containing novel agents are available before transplantation. Elderly patients are usually not eligible for transplantation, and gentler approaches with new drugs combinations are used for their treatment.


Asunto(s)
Humanos , Factores de Edad , Antineoplásicos/uso terapéutico , Ácidos Borónicos/uso terapéutico , Factores Inmunológicos/uso terapéutico , Mieloma Múltiple/diagnóstico , Pronóstico , Pirazinas/uso terapéutico , Trasplante de Células Madre , Talidomida/análogos & derivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA